Background Although several therapeutic agents have been evaluated for the treatment of
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …

BACKGROUND: Although several therapeutic agents have been evaluated for the treatment
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …

Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro
and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We …

Background Efficacy and safety of treatments for hospitalized COVID-19 are uncertain. We
systematically reviewed efficacy and safety of remdesivir for the treatment of COVID-19 …

Background We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-
care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a …

Objectives We performed a systematic review and network meta-analysis of randomized
controlled trials (RCTs) to provide updated information regarding the clinical efficacy of …

Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

Importance Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …

Background In view of many unanswered clinical questions regarding treatment of COVID-
19 with remdesivir, we systematically identified, critically appraised and summarized the …

Remdesivir is an antiviral agent that has shown broad‐spectrum activity, including against
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clinical trials investigating …